Alzheimer Disease, Early Onset Clinical Trial
Official title:
Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease (ART-AD)
The objective of the study is to evaluate the ability of (-)-L-2',3'-dideoxy-3'-thiacytidine (3TC) to engage its intended target, penetrate the central nervous system (CNS), suppress neurodegeneration, and assess safety and tolerability in patients with early stage Alzheimer's disease. This study will provide the initial data on target engagement and Alzheimer's disease-relevant outcomes for future trials.
This open label study of 3TC will collect initial proof-of-concept data on 3TC target engagement, CNS penetration, efficacy and safety in older adults with early stage Alzheimer's disease. If successful, data will be used to design a larger phase 2 clinical trial. The investigators aim to I) Quantify 3TC target engagement and CNS penetration, II) Determine if 3TC suppresses Alzheimer's disease-relevant outcomes, and III) Assess the safety and tolerability of 3TC in older individuals with early Alzheimer's disease. The study will consist of a screening/baseline period of 30 days pre-treatment, a 24-week open label treatment period, and a follow up visit one month following treatment. Visits to the clinic include a pre-treatment screening visit that includes a comprehensive neuropsychological exam, a tablet-based neuropsychological exam, and a blood draw. For eligible participants, a lumbar puncture will be performed on day one of treatment. Participants will visit the clinic on day one of treatment and at weeks 8, 16, and 24 of treatment to complete medication checks, physical examinations, tablet-based cognitive screening, and blood draw. At week 24 of treatment, patients will undergo a post-treatment comprehensive neuropsychological exam, a lumbar puncture to collect cerebrospinal fluid, and a blood draw. One month after the final dose of medication, participants will return to the clinic for a final safety assessment and disenrollment. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03625401 -
Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease
|
Phase 2 | |
Not yet recruiting |
NCT05882344 -
Deep Brain Stimulation for Alzheimer's
|
N/A | |
Not yet recruiting |
NCT05604183 -
Hyperspectral Retinal Observations for the Cross-sectional Detection of Alzheimer's Disease
|
N/A | |
Withdrawn |
NCT03514875 -
Effects of Mitochondrial-targeted Antioxidant on Mild Cognitive Impairment (MCI) Patients
|
N/A | |
Completed |
NCT03706885 -
Efavirenz for Patients With Alzheimer's Disease
|
Phase 1 | |
Active, not recruiting |
NCT03661034 -
Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study)
|
N/A | |
Not yet recruiting |
NCT05006599 -
SNIFF - 3-Week Aptar CPS Device
|
Phase 2 | |
Active, not recruiting |
NCT03069391 -
The Interactive Physical and Cognitive Exercise System
|
N/A | |
Recruiting |
NCT04701957 -
The Ketogenic Diet for Alzheimer's Disease
|
N/A | |
Recruiting |
NCT04100889 -
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease
|
||
Recruiting |
NCT04656860 -
Juice Plus Supplement Clinical Trial
|
N/A | |
Recruiting |
NCT05315895 -
The Dampness Syndrome of Chinese Medicine Cohort Study
|
||
Recruiting |
NCT04916964 -
Adapted Home-based Exercise Program "T&E" (Test-and-Exercise) in Persons With Alzheimer's Disease (HOPE Trial)
|
N/A | |
Recruiting |
NCT04804618 -
Proteomics Study of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Recruiting |
NCT04680013 -
Genetic Studies in Familial Dementia
|
||
Not yet recruiting |
NCT05573490 -
Lifestyle Interventions for the Treatment of Early Onset Alzheimer's Disease Study
|
N/A | |
Completed |
NCT00909285 -
Effects of Transcranial Magnetic Stimulation (TMS) and Cognitive Training for Alzheimer Patients
|
N/A | |
Not yet recruiting |
NCT04427436 -
Novel Dementia Biomarkers
|
||
Completed |
NCT05406648 -
The Effect of Black Mulberry (Morus Nigra) Consumption on Cognitive Functions
|
N/A | |
Completed |
NCT03508024 -
Patients With Alzheimer's Disease or Related Youth Disease
|